Merit Medical Systems SG&A Expenses 2010-2023 | MMSI
Merit Medical Systems sg&a expenses from 2010 to 2023. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
Merit Medical Systems Annual SG&A Expenses
(Millions of US $) |
| 2023 |
$374 |
| 2022 |
$343 |
| 2021 |
$336 |
| 2020 |
$298 |
| 2019 |
$327 |
| 2018 |
$276 |
| 2017 |
$229 |
| 2016 |
$184 |
| 2015 |
$156 |
| 2014 |
$148 |
| 2013 |
$129 |
| 2012 |
$122 |
| 2011 |
$105 |
| 2010 |
$88 |
| 2009 |
$65 |
Merit Medical Systems Quarterly SG&A Expenses
(Millions of US $) |
| 2023-12-31 |
$96 |
| 2023-09-30 |
$87 |
| 2023-06-30 |
$101 |
| 2023-03-31 |
$90 |
| 2022-12-31 |
$83 |
| 2022-09-30 |
$90 |
| 2022-06-30 |
$85 |
| 2022-03-31 |
$84 |
| 2021-12-31 |
$77 |
| 2021-09-30 |
$86 |
| 2021-06-30 |
$92 |
| 2021-03-31 |
$81 |
| 2020-12-31 |
$80 |
| 2020-09-30 |
$72 |
| 2020-06-30 |
$67 |
| 2020-03-31 |
$79 |
| 2019-12-31 |
$82 |
| 2019-09-30 |
$87 |
| 2019-06-30 |
$80 |
| 2019-03-31 |
$78 |
| 2018-12-31 |
$76 |
| 2018-09-30 |
$66 |
| 2018-06-30 |
$69 |
| 2018-03-31 |
$65 |
| 2017-12-31 |
$59 |
| 2017-09-30 |
$55 |
| 2017-06-30 |
$57 |
| 2017-03-31 |
$58 |
| 2016-12-31 |
$46 |
| 2016-09-30 |
$53 |
| 2016-06-30 |
$44 |
| 2016-03-31 |
$42 |
| 2015-12-31 |
$41 |
| 2015-09-30 |
$39 |
| 2015-06-30 |
$39 |
| 2015-03-31 |
$37 |
| 2014-12-31 |
$36 |
| 2014-09-30 |
$36 |
| 2014-06-30 |
$39 |
| 2014-03-31 |
$37 |
| 2013-12-31 |
$34 |
| 2013-09-30 |
$31 |
| 2013-06-30 |
$32 |
| 2013-03-31 |
$32 |
| 2012-12-31 |
$33 |
| 2012-09-30 |
$29 |
| 2012-06-30 |
$30 |
| 2012-03-31 |
$30 |
| 2011-12-31 |
$28 |
| 2011-09-30 |
$26 |
| 2011-06-30 |
$26 |
| 2011-03-31 |
$25 |
| 2010-12-31 |
$26 |
| 2010-09-30 |
$22 |
| 2010-06-30 |
$20 |
| 2010-03-31 |
$19 |
| 2009-12-31 |
$17 |
| 2009-09-30 |
$17 |
| 2009-06-30 |
$16 |
| 2009-03-31 |
$15 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$4.697B |
$1.257B |
|
Merit Medical Systems, Inc. provides various peripheral and cardiac intervention products to cure cardiac conditions specific to interventional cardiology and electrophysiology. The company offers products focused in five core product groups: peripheral intervention, cardiac intervention, interventional oncology and spine, cardiovascular and critical care as well as endoscopy. However, the company operates in two revenue segments: Cardiovascular and Endoscopy Devices.
|
